EJC Supplements

Published by: Pergamon-Elsevier Science Ltd  

People

  1. Hamlin
    Hamlin
  2. Zelenetz
    Zelenetz
  3. Aghajanian
    Aghajanian
  4. Chiosis
    Chiosis
  5. Fleisher
    Fleisher
  6. Horwitz
    Horwitz
  7. Noy
    Noy
  8. Rodina Balingcongan
    Rodina Balingcongan
  9. Sawyers
    Sawyers
  10. Scher
    Scher

Groups

  1. Center for Hematologic Malignancies (6)
  2. Department of Medicine (4)
  3. Hematologic Malignancies, Division of (4)
  4. Lymphoma (3)
  5. GSK Faculty (2)
  6. Molecular Pharmacology and Chemistry Program Faculty (2)
  7. Sloan Kettering Institute Faculty (2)
  8. Solid Tumor Oncology Division (2)
  9. Executive Committee, Center for Hematologic Malignancies (1)
  10. GDMT, Medicine (1)
Search Within
  1. "Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (6)
Groups
  1. Center for Hematologic Malignancies (6)
  2. Department of Medicine (4)
  3. Hematologic Malignancies, Division of (4)
  4. Lymphoma (3)
  5. GSK Faculty (2)
  6. Molecular Pharmacology and Chemistry Program Faculty (2)

More Groups

People
  1. Andrew Zelenetz (2)
  2. Craig Moskowitz (2)
  3. Owen O'connor (2)
  4. Paul Hamlin (2)
  5. Anna Rodina Balingcongan (1)
  6. Ariela Noy (1)

More People

Years
  1. 2008 (2)
  2. 2006 (2)
  3. 2005 (1)
  4. 2003 (1)
Publishers
  1. Pergamon-Elsevier Science Ltd (6)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I-II study of MDV3100 in castration resistant prostate cancer. The Prostate Cancer Clinical Trials consortium
    Meeting Abstract

    Scher, H.; Beer, T.; Higano, C.; Logothetis, C.; Shelkey, J.; Hung, D.; Hirmand, M.; Larson, S.; Fleisher, M.; Sawyers, C.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • NPI-0052 (a 2nd generation proteasome inhibitor) Phase 1 study in patients with lymphoma and solid tumors
    Meeting Abstract

    Kurzrock, R.; Hamlin, P.; Gordon, M.; Hong, D.; Fu, S.; Younes, A.; Hannah, A.; Palladino, M. A.; Spear, M. A.; Aghajanian, C.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • Early phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies
    Meeting Abstract

    O'connor, O.; Hamlin, P.; Neylon, E.; Moskowitz, C.; Portlock, C.; Noy, A.; Sirotnak, F.; Zelenetz, A.; Mould, D.; Horwitz, S.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Defining Hsp90 as inhibitor of apoptosis in small cell lung cancer
    Meeting Abstract

    Chiosis, G.; Rodina, A.; Kim, J.; Aguirre, J.; Moulick, K.; Lopes, E. C.; Wu, N.; She, Y.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: A rare cancer network study
    Meeting Abstract

    Ozyar, E.; Selek, U.; Laskar, S.; Uzel, O.; Anacak, Y.; Ben-Arush, M.; Polychronopoulou, S.; Akman, F.; Wolden, S.; Sarihan, S.
    EJC Supplements (2005)

    Fulltext@MSK | Save
  • Phase II clinical experience with the novel proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent and mantle cell lymphomas
    Meeting Abstract

    O'Connor, O. A.; Wright, J.; Moskowitz, C.; Straus, D.; Macgregor-Cortelli, B.; Muzzy, J.; Choi, P.; Schenkein, D.; Zelenetz, A. D.
    EJC Supplements (2003)

    Fulltext@MSK | Save

    • EJC Supplements – authorized name for:

    Name ISSN / ISBN Publisher
    EJC Supplements 1359-6349 Pergamon-Elsevier Science Ltd
    EJC Supplements 1359-6349 Unknown
    European Journal of Cancer Supplements 1359-6349 Elsevier Inc.
    European Journal of Cancer Supplements 1359-6349 Elsevier Inc.
    European Journal of Cancer Supplements 1359-6349 Pergamon-Elsevier Science Ltd
    European Journal of Cancer, Supplement 13596349 Elsevier Inc.
    European Journal of Cancer, Supplement 13596349 Unknown